[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335044-105":59,"doc-detail-335044-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","car-t-lymphocyte-based-cell-therapies-mechanistic-substantiation-applications-and-biosafety-enhancement-with-suicide-genes-new-opportunities-to-melt-side-effects","CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects","","CAR-T lymphocyte-based cell therapies represent a genetically engineered form of adoptive immunotherapy that uses chimeric antigen receptor T cells to recognize tumor antigens and eliminate malignant cells. This review surveys CAR-T technology from structural optimization and successive generations to manufacturing workflows and gene-therapy strategies. It evaluates applications across hematologic malignancies and solid tumors, emphasizing persistent challenges and side effects. A suicide gene-based approach is discussed as a mechanistic safety enhancement, aiming to reduce cytokine release syndrome and related neurotoxicity while improving efficacy and biosafety for oncology patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-lymphocyte-based-cell-therapies-mechanistic-substantiation-applications-and-biosafety-enhancement-with-suicide-genes-new-opportunities-to-melt-side-effects/335044/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-lymphocyte-based-cell-therapies-mechanistic-substantiation-applications-and-biosafety-enhancement-with-suicide-genes-new-opportunities-to-melt-side-effects/335044.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What makes CAR-T a promising approach for cancer treatment?","Question",{"text":113,"@type":114},"CAR-T uses genetically engineered T lymphocytes designed to recognize specific tumor antigens and eliminate tumor cells. It is discussed as a way to combine and extend immunotherapy strategies such as checkpoint blockade and adoptive T cell transfer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which areas does the review cover regarding CAR-T cell technology?",{"text":118,"@type":114},"The review covers structure optimization, CAR-T generations, manufacturing processes, and gene therapy strategies. It also addresses how these factors translate into treatment for different cancer types.",{"name":120,"@type":111,"acceptedAnswer":121},"How do suicide genes aim to improve CAR-T biosafety?",{"text":122,"@type":114},"The review proposes a suicide gene-based mechanism to mitigate side effects, particularly cytokine release syndrome, which is identified as the most common toxic effect. It also targets associated neurotoxicity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335044,1790176735,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","TYPE Review  \nPUBLISHED 18 July 2024  \nDOI 10.3389/fimmu.2024.1333150  \nOPEN ACCESS  \nEDITED BY  \nSina Naserian,  \nHoˆ pital Paul Brousse, France  \nREVIEWED BY  \nAntonio Di Stasi,  \nUniversity of Alabama at Birmingham, United States  \nMohamed Essameldin Abdelgawad, Wake Forest University, United States  \n*CORRESPONDENCE Carmen Ramrez-Castillejo  \n [carmen.ramirez@ctb.upm.es](carmen.ramirez@ctb.upm.es)[ ](carmen.ramirez@ctb.upm.es)Raquel Gonz´alez-Martos  \n [raquel.gonzalez@ctb.upm.es](raquel.gonzalez@ctb.upm.es)  \nRECEIVED 04 November 2023  \nACCEPTED 14 June 2024  \nPUBLISHED 18 July 2024  \nCITATION  \nErcilla-Rodrguez P, S´anchez-Dez M, Alegra-Aravena N, Quiroz-Troncoso J, Gavira-O'Neill CE, Gonza´lez-Martos R and Ramrez-Castillejo C (2024) CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.  \nFront. Immunol. 15:1333150 .  \ndoi: 10.3389/fimmu.2024.1333150  \nCOPYRIGHT  \n© 2024 Ercilla-Rodrguez, Sa´nchez-Dez, Alegra-Aravena, Quiroz-Troncoso, Gavira-O'Neill, Gonz´alez-Martos and Ramrez-Castillejo. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects  \nPaula Ercilla-Rodr ´ıguez 1, Marta S´anchez-D ´ıez 1,2, Nicol´as Alegr ´ıa-Aravena 3,4, Josefa Quiroz-Troncoso 1,2, Clara E. Gavira-O'Neill 2,5, Raquel Gonz´alez-Martos 1,2* and Carmen Ram ´ırez-Castillejo 1,2,5*  \n1 ETSIAAB, Universidad Polite´cnica de Madrid, Madrid, Spain, 2 Laboratorio Cancer Stem Cell, HST group, Centro de Tecnologa Biome´ dica, Universidad Polite´cnica de Madrid, Madrid, Spain, 3Grupo de Biologa y Produccio´ n de Ce´ rvidos, Instituto de Desarrollo Regional, Universidad de Castilla-La Mancha, Albacete, Spain, 4Asociacio´n Española Contra el C´ancer (AECC)-Fundacio´n Cientﬁca AECC, Albacete, Spain, 5Seccio´n de Oncologa, Instituto de Investigacio´n Sanitaria San Carlos, Madrid, Spain  \nImmunotherapy has made signiﬁcant strides in cancer treatment with strategies like checkpoint blockade antibodies and adoptive T cell transfer. Chimeric antigen receptor T cells (CAR-T) have emerged as a promising approach to combine these strategies and overcome their limitations. This review explores CAR-T cells as a living drug for cancer treatment. CAR-T cells are genetically engineered immune cells designed to target and eliminate tumor cells by recognizing speciﬁc antigens. The study involves a comprehensive literature review on CAR-T cell technology, covering structure optimization, generations, manufacturing processes, and gene therapy strategies. It examines CAR-T therapy in haematologic cancers and solid tumors, highlighting challenges and proposing a suicide gene-based mechanism to enhance safety. The results show signiﬁcant advancements in CAR-T technology, particularly in structure optimization and generation. The manufacturing process has improved for broader clinical application. However, a series of inherent challenges and side effects still need to be addressed. In conclusion, CAR-T cells hold great promise for cancer treatment, but ongoing research is crucial to improve efﬁcacy and safety for oncology patients. The proposed suicide gene-based mechanism offers a potential solution to mitigate side effects including cytokine release syndrome (the most common toxic side effect of CAR-T therapy) and the associated neurotoxicity.  \nKEYWORDS  \nCAR-T, cell therapy, immune response, adoptive immunother","cbCaijul2PGWwxb6","https://ap.wps.com/l/cbCaijul2PGWwxb6","pdf",2622967,22,"English","# Introduction\n# CAR-T as a living drug for cancer therapy\n## Engineering and structure optimization\n## Generations and manufacturing processes\n# Applications in hematologic cancers and solid tumors\n## Challenges and adverse effects\n# Suicide gene-based biosafety enhancement","[{\"question\":\"What makes CAR-T a promising approach for cancer treatment?\",\"answer\":\"CAR-T uses genetically engineered T lymphocytes designed to recognize specific tumor antigens and eliminate tumor cells. It is discussed as a way to combine and extend immunotherapy strategies such as checkpoint blockade and adoptive T cell transfer.\"},{\"question\":\"Which areas does the review cover regarding CAR-T cell technology?\",\"answer\":\"The review covers structure optimization, CAR-T generations, manufacturing processes, and gene therapy strategies. It also addresses how these factors translate into treatment for different cancer types.\"},{\"question\":\"How do suicide genes aim to improve CAR-T biosafety?\",\"answer\":\"The review proposes a suicide gene-based mechanism to mitigate side effects, particularly cytokine release syndrome, which is identified as the most common toxic effect. It also targets associated neurotoxicity.\"}]","CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects | PDF",1790009434,55]